Supporting the hypothesis that myostatin inhibition will convey a functional benefit to DMD patients, at least two other myostatin inhibitor drug candidates are in clinical testing for DMD: BMS-986089, a myostatin adnectin (ClinicalTrials.gov identifier# NCT02515669) and rAAV1.CMV.huFollistatin344, follistatin gene therapy, (ClinicalTrials.gov identifier# NCT02354781). Here, MSTN is linked to Duchenne muscular dystrophy.